In addition to mutations existing in the predominant cell population of the tumor before treatment, overall resistance to therapy can arise during anti-EGFR therapy, as the drug can inhibit growth of sensitive clones, thereby allowing for expansion of initially rare RAS-mutant clones (10, 62). The gene discussed is EGFR; the disease is neoplasm.